Blood News and Research

RSS

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

FDA clears non-invasive test to help manage heart transplant patients

The U.S. Food and Drug Administration has announced it has cleared for marketing a non-invasive test that uses molecular expression techniques to assist doctors in managing heart transplant patients post-surgery for potential organ rejection.

27 Aug 2008

Young type-2 diabetic men suffer low testosterone levels

Young men with type 2 diabetes have significantly low levels of testosterone, endocrinologists at the University at Buffalo have found -- a condition that could have a critical effect on their quality of life and on their ability to father children.

27 Aug 2008

Chronic stress alters our genetic immune response

Most people would agree that stress increases your risk for illness and this is particularly true for severe long-term stresses, such as caring for a family member with a chronic medical illness. However, we still have a relatively limited understanding of exactly how stress contributes to the risk for illness. In the August 15th issue of Biological Psychiatry, researchers shed new light on one link between stress and illness by describing a mechanism through which stress alters immune function.

27 Aug 2008

Alabama board approves plan to charge state employees for obesity, health problems

The Alabama State Employees' Insurance Board last week approved a plan that will require state employees who are obese or have health problems to make progress to address those issues or pay a monthly charge for health insurance, the AP/Philadelphia Inquirer reports.

26 Aug 2008

High cholesterol levels drop naturally in children on high-fat antiseizure diet

Elevated cholesterol levels return to normal or near normal levels over time in four out of 10 children with uncontrollable epilepsy treated with the high-fat ketogenic diet, according to results of a Johns Hopkins Children's Center study reported in the Journal of Child Neurology.

26 Aug 2008

Olive leaf extract (EFLA943) helps tackle high blood pressure and cholesterol

Taking 1000mg of a specific olive leaf extract (EFLA943) can lower cholesterol and lower blood pressure in patients with mild hypertension (high blood pressure).

26 Aug 2008

Early trigger for type-1 diabetes found in mice

Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins.

26 Aug 2008

Role of vitamin D in kidney disease examined

Vitamin D is the key to preventing rickets and osteoporosis, but Rockefeller University scientists suspect it may also play a role in heading off atherosclerosis in people with chronic kidney disease.

26 Aug 2008

Normalizing tumor vessels to improve chemotherapy drug delivery

Chemotherapy drugs often never reach the tumors they're intended to treat, and radiation therapy is not always effective, because the blood vessels feeding the tumors are abnormal-"leaky and twisty" in the words of the late Judah Folkman, MD, founder of the Vascular Biology program at Children's Hospital Boston.

25 Aug 2008

New technique offers hope for stroke sufferers

If a stroke patient doesn't get treatment within approximately the first three hours of symptoms, there's not much doctors can do to limit damage to the brain.

25 Aug 2008

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer?

Prof. Eliezer Flescher of The Sackler Faculty of Medicine, Tel Aviv University thinks so. He and his colleagues have developed an anti-cancer drug based on a decade of research into the commercial applications of the compound Jasmonate, a synthetic compound derived from the flower itself.

25 Aug 2008

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Study reveals how blood flow force protects against atherosclerosis

Machines on cell surfaces, mechanical and lifeless as bed springs, protect blood vessels by responding to blood flow force, according to research published today in the Journal of Cell Biology. By sensing and reacting to force, such machines interfere with inflammatory pathways central to atherosclerosis, the cause of clogged arteries that lead to heart attack and stroke, the authors said. The next set of studies, already underway, seeks to "tweak" the process with the goal of designing a new class of therapies.

25 Aug 2008